Our finding may also provide an explanation for the therapeutic benefits of glucagon receptor agonists for individuals with obesity and type 2 diabetes reported recently in clinical trials (72, 73). The gene discussed is GCGR; the disease is obesity due to melanocortin 4 receptor deficiency.